HOUSTON, April 27, 2021 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, today
announced that the 52-week results from its pivotal cellulite trial
have been accepted for an oral presentation at the American Society
for Laser Medicine and Surgery Virtual Annual Conference, held
May 15-16, 2021.
"We are honored to present new long-term cellulite data at the
ASLMS annual conference. We are extremely encouraged by the 52-week
findings from our pivotal cellulite trial which demonstrate the
potential of our RESONIC device to reduce the appearance of
cellulite long-term," commented Brad
Hauser, Soliton CEO and President. "We look forward to
sharing these results in front of the well-respected industry
members and community attending ASLMS."
------------------------
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
------------------------
Details of the presentation include:
Abstract Title: PATIENT SATISFACTION WITH THE
IMPROVEMENT IN THE APPEARANCE OF CELLULITE RESULTING FROM A SINGLE
NON-INVASIVE TREATMENT WITH A RAPID ACOUSTIC PULSE DEVICE CAUSING
ACOUSTIC SUBCISION: INTERIM 52-WEEKS FINDINGS FROM A MULTI-CENTER
PIVOTAL TRIAL
Presentation Category: Emerging Technologies
Parent Session: Clinical Applications B
Presenting Author Name: Elizabeth Tanzi, MD
Presentation Date and Time: Saturday, May 15, 2021 11:23 – 11:28 a.m. CT
About Soliton
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product,
RESONIC™, will use rapid pulses of acoustic shockwaves for the
treatment of cellulite and as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing RESONIC to the market. The Company believes this "Soliton"
method has the potential to lower tattoo removal costs for
patients, while increasing profitability to practitioners, compared
to current laser removal methods. The Company also believes the
technology will provide the first non-invasive acoustic technology
to target the underlying causes of dimples and ridges in cellulite.
Soliton is investigating potential additional capabilities of the
RAP technology. The device is currently cleared in the United States only for use in tattoo
removal and cellulite.
For more information about the Company, please visit:
http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to effectively
treat cellulite with long-term results. These statements
relate to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
actual results or outcomes may prove to be materially different
from the expectations expressed or implied by such forward-looking
statements. Soliton has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would,"
''should,'' ''approximately'' or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including those discussed in our filings with the
Securities and Exchange Commission ("SEC"), including under the
heading " Risk Factors" in our most recently filed Form 10-K filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-oral-presentation-at-american-society-for-laser-medicine-and-surgery-virtual-annual-conference-301271629.html
SOURCE Soliton, Inc.